- Home
- HYPR vs PMN Comparison
HYPR vs PMN Comparison
Compare HYPR & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYPR | PMN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.7M | 115.5M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HYPR | PMN |
|---|---|---|
| Price | $1.66 | $10.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $1.59 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 739.5K | 28.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.21 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,563,000.00 | N/A |
| Revenue This Year | $50.75 | N/A |
| Revenue Next Year | $29.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.22 | N/A |
| 52 Week Low | $0.58 | $0.29 |
| 52 Week High | $2.22 | $27.40 |
Technical Indicators
Market Signals| Indicator | HYPR | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 59.94 | 42.54 |
| Support Level | $1.04 | $10.55 |
| Resistance Level | $1.94 | $13.80 |
| Average True Range (ATR) | 0.10 | 0.56 |
| MACD | -0.02 | 0.18 |
| Stochastic Oscillator | 64.04 | 61.01 |
Price Performance
Historical ComparisonAbout HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.